David R Stover
Overview
Explore the profile of David R Stover including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Safaie T, Trinh K, Vasuthasawat A, Morrison S, Stover D
J Interferon Cytokine Res
. 2024 Jul;
44(9):414-423.
PMID: 38949948
No abstract available.
2.
Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, Ou J, et al.
Cancer Res
. 2018 Feb;
78(8):2115-2126.
PMID: 29382707
AGS-16C3F is an antibody-drug conjugate (ADC) against ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) containing the mcMMAF linker-payload currently in development for treatment of metastatic renal cell carcinoma. AGS-16C3F and other ADCs have...
3.
Zhao H, Gulesserian S, Ganesan S, Ou J, Morrison K, Zeng Z, et al.
Mol Cancer Ther
. 2017 Jun;
16(9):1877-1886.
PMID: 28655784
Thrombocytopenia is a common adverse event in cancer patients treated with antibody-drug conjugates (ADC), including AGS-16C3F, an ADC targeting ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase-3) and trastuzumab emtansine (T-DM1). This study aims to...
4.
Zhao H, Gulesserian S, Malinao M, Ganesan S, Song J, Chang M, et al.
Mol Cancer Ther
. 2017 May;
16(9):1866-1876.
PMID: 28522588
Neutropenia is a common adverse event in cancer patients treated with antibody-drug conjugates (ADC) and we aimed to elucidate the potential mechanism of this toxicity. To investigate whether ADCs affect...
5.
Mattie M, Raitano A, Morrison K, Morrison K, An Z, Capo L, et al.
Mol Cancer Ther
. 2016 Aug;
15(11):2679-2687.
PMID: 27550944
Here, we report the development of an antibody-drug conjugate, ASG-5ME, which targets the solute carrier receptor SLC44A4. SLC44A4 is a member of a family of putative choline transporters that we...
6.
Campbell D, Noda A, Verlinsky A, Snyder J, Fujita Y, Murakami Y, et al.
Mol Imaging Biol
. 2016 Apr;
18(5):768-75.
PMID: 27122234
Purpose: Nectin-4 is selectively overexpressed in a variety of cancers and is currently under clinical investigation as a therapeutic target. A monoclonal antibody against nectin-4 (AGS-22M6) was evaluated as an...
7.
Challita-Eid P, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al.
Cancer Res
. 2016 Mar;
76(10):3003-13.
PMID: 27013195
The identification of optimal target antigens on tumor cells is central to the advancement of new antibody-based cancer therapies. We performed suppression subtractive hybridization and identified nectin-4 (PVRL4), a type...
8.
Morrison K, Challita-Eid P, Raitano A, An Z, Yang P, Abad J, et al.
Mol Cancer Ther
. 2016 Mar;
15(6):1301-10.
PMID: 26944921
SLITRK6 is a member of the SLITRK family of neuronal transmembrane proteins that was discovered as a bladder tumor antigen using suppressive subtractive hybridization. Extensive immunohistochemistry showed SLITRK6 to be...
9.
Donate F, Raitano A, Morrison K, An Z, Capo L, Avina H, et al.
Clin Cancer Res
. 2015 Nov;
22(8):1989-99.
PMID: 26589436
Purpose: New cancer-specific antigens are required for the design of novel antibody-drug conjugates (ADC) that deliver tumor-specific and highly potent cytotoxic therapy. Experimental Design: Suppression subtractive hybridization identified ectonucleotide pyrophosphatase/phosphodiesterase...
10.
Pereira D, Guevara C, Jin L, Mbong N, Verlinsky A, Hsu S, et al.
Mol Cancer Ther
. 2015 May;
14(7):1650-60.
PMID: 25934707
CD37 is a tetraspanin expressed on malignant B cells. Recently, CD37 has gained interest as a therapeutic target. We developed AGS67E, an antibody-drug conjugate that targets CD37 for the potential...